Several studies have suggested that focal adhesion kinase (FAK) expression is frequently upregulated in different types of cancer, including NSCLC, and a number of studies have focused on either reducing FAK expression or activity to inhibit the growth and metastatic capacities of tumors [128, 129]. The gene discussed is PTK2; the disease is cancer.